AIM ImmunoTech Publishes Investor Presentation on Ampligen’s Potential in Pancreatic Cancer

Bitget2026/11/05 14:15

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

AIM ImmunoTech published its investor presentation, “The Ampligen Opportunity,” outlining potential pancreatic cancer treatment combinations.
The presentation explores adding Ampligen to daraxonrasib or using it as maintenance therapy; safety and efficacy remain unestablished.
Phase 2 DURIPANC topline results are expected in Q1 2027, with additional clinical and immune-response analyses anticipated in Q3 2027.
The presentation is available at https://www.globenewswire.com/Tracker?data=QdZ8pSW0q2S07PT-VQo9S4V_PVOO56l13GkI0nPb7IFXZ_XT0L1zP9RW7F8shcF1aaasCRe01E-7dO8jz31z8qw2e50hDys2GqFpdU-Hrrs=.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AIM ImmunoTech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611050913PRIMZONEFULLFEED9871033) on November 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

AIM ImmunoTech Publishes Investor Presentation on Ampligen’s Potential in Pancreatic Cancer

You may also like

Crypto prices